QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What ...
uniQure’s Ifezuntirgene slowed disease progression by 80% on a measure combining movement, thinking and daily function. Slowing of disease progression fell to 44% over a 48-month period. Five patients experienced serious treatment-related inflammation in …